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Type II enteropathy-associated T-cell lymphoma
features a unique genomic proﬁle with highly
recurrent SETD2 alterations
Annalisa Roberti1, Maria Pamela Dobay2, Bettina Bisig1, David Vallois1, Cloe´ Boe´chat1, Evripidis Lanitis3,
Brigitte Bouchindhomme4, Marie- Ce´cile Parrens5, Ce´line Bossard6, Leticia Quintanilla-Martinez7,
Edoardo Missiaglia1,2, Philippe Gaulard8 & Laurence de Leval1
Enteropathy-associated T-cell lymphoma (EATL), a rare and aggressive intestinal malignancy
of intraepithelial T lymphocytes, comprises two disease variants (EATL-I and EATL-II)
differing in clinical characteristics and pathological features. Here we report ﬁndings derived
from whole-exome sequencing of 15 EATL-II tumour-normal tissue pairs. The tumour
suppressor gene SETD2 encoding a non-redundant H3K36-speciﬁc trimethyltransferase is
altered in 14/15 cases (93%), mainly by loss-of-function mutations and/or loss of the
corresponding locus (3p21.31). These alterations consistently correlate with defective H3K36
trimethylation. The JAK/STATpathway comprises recurrent STAT5B (60%), JAK3 (46%) and
SH2B3 (20%) mutations, including a STAT5B V712E activating variant. In addition, frequent
mutations in TP53, BRAF and KRAS are observed. Conversely, in EATL-I, no SETD2, STAT5B or
JAK3 mutations are found, and H3K36 trimethylation is preserved. This study describes
SETD2 inactivation as EATL-II molecular hallmark, supports EATL-I and -II being two distinct
entities, and deﬁnes potential new targets for therapeutic intervention.
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E
nteropathy-associated T-cell lymphoma (EATL) is a
rare peripheral T-cell lymphoma entity derived from
intraepithelial intestinal cytotoxic T lymphocytes1. The
current WHO classiﬁcation recognizes two disease variants,
which differ by epidemiology, clinical features, morphology and
immunophenotype: type I (EATL-I), and type II (EATL-II).
EATL-I, most frequent in Europe and often associated
with coeliac sprue, usually features pleomorphic morphology
comprising medium to large cells with frequent CD30 expression,
an inﬂammatory component, and frequent necrosis. EATL-II, is
less common overall, but in contrast to EATL-I infrequently
associates with coeliac sprue and occurs worldwide. EATL-II also
termed monomorphic CD56þ intestinal T-cell lymphoma, or
monomorphic epitheliotropic intestinal T-cell lymphoma2,
is composed of CD3þ CD8þ CD56þ monomorphic
medium-sized cells with round nuclei and pale cytoplasm,
showing marked epitheliotropism to the adjacent intestinal
mucosa. In the majority of cases the neoplastic cells are derived
from gd-T cells, although some cases are of ab-T-cell derivation
and a minority of cases may be either double positive or
double negative for T-cell receptor (TCR) beta and TCR gamma
expression1,3–5. An inﬂammatory inﬁltrate is typically absent
and necrosis is less frequent than in EATL-I. Both subtypes are
highly aggressive disorders with 5-year survival rates below 20%
(ref. 6) and few treatment options available.
The genetic basis of EATL-II still remains poorly characterized,
mainly restricted to copy number alterations7–9 and targeted
sequencing studies10,11. Comparative genomic hybridization
(CGH)-based studies have shown that both types share common
recurrent chromosomal imbalances, and also distinctive genetic
alterations. Regardless of the subtype, EATL is cytogenetically
characterized by chromosome 9q gains and almost mutually
exclusive losses of 16q12.1. Gain of chromosome 7 and losses of
8p22-23.2, 16q21.1, 11q14.1-q14.2 and 9p21.2-p21.3 are also
frequent in both EATL variants. Conversely, EATL-II is
characterized by signiﬁcantly more frequent gains of the MYC
oncogene locus and less-frequent gains of chromosomes 1q and 5q
as compared with EATL-I, suggesting two distinct genetic
pathways. In addition, the loss of 3p21.31 has been reported as
recurrent in type II but not in type I EATL.
Recent works have pointed at the implication of the JAK/STAT
pathway in EATL-II. Recurrent mutations of STAT5B in EATL-II
were ﬁrst reported in 2015 and found to occur exclusively in cases
of gd origin11. The study by Nairismagi et al.10 further
substantiated recurrent mutations mainly affecting hotspots in
STAT5B and JAK3.
Here we sought to deﬁne the genetic landscape of EATL-II by
performing whole-exome sequencing (WES) on a series of 15
paired tumour-normal EATL-II samples. The highlight of our
study is the discovery of frequent alterations of the tumour
suppressor SETD2 gene by loss-of-function mutations and/or loss
of the corresponding 3p.21 locus in the majority of the cases
(14/15). Our ﬁndings also further expand the documentation of
frequent improper activation of the JAK/STAT5 pathway,
principally by recurrent mutations in STAT5B (60%), JAK3
(46%) and SH2B3 (20%). In addition, we show that in EATL-I,
SETD2 alterations are not found while a distinct pattern of
JAK/STAT mutations is observed, supporting that both EATL
variants correspond to distinct pathological entities.
Results
Genomic landscape of EATL-II. The outline of our study is
depicted in Supplementary Fig. 1. For the majority of our cases
only formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue was
available for analysis. Thus, starting from the notion that
fresh-frozen material represents a benchmark for WES technique,
as a ﬁrst step we validated the quality of our WES protocol and
bioinformatics pipeline on FFPE samples by comparing two
paired normal/tumour DNA samples of intestinal lymphomas for
which both fresh-frozen and FFPE tissue samples were available
(one EATL-II, corresponding to case 1 of our cohort, and one
intestinal ALK-positive anaplastic large cell lymphoma; Methods
and Supplementary Figs 2 and 3). Having shown a very good
concordance between results generated from fresh-frozen
and FFPE materials, we then performed WES of 15 paired
tumour-normal DNA samples isolated by microdissection of
routinely processed FFPE EATL-II surgical samples
(Supplementary Table 1).
WES produced a mean coverage of 195 and 213 for
tumour and normal samples, respectively, with around 89% of the
target sequence covered by at least 50 reads. Overall, we found a
total of 3,488 somatic mutations, including 1,393 non-silent
mutations in 1,205 genes, with a median of 57 (range 31–555)
somatic non-synonymous mutations per patient (average of 1.7
per Mb). As in other tumours, C4T transitions were the
most frequent exonic mutations (B50%), followed by C4A
transversions (12%) (Fig. 1a and Supplementary Data 1).
Validation performed by Sanger sequencing and/or targeted deep
sequencing on 59 variants selected from the most relevant genes,
showed 91% concordance across the different methods used
(Supplementary Data 1 and Supplementary Tables 2 and 3).
The mutational landscape of EATL-II was remarkably
homogeneous showing signiﬁcantly enriched clusters among
histone modiﬁer genes, JAK-STAT and MAPK-signalling
pathways (Fig. 1b and Supplementary Data 2). The Histone-
lysine N-methyltransferase SETD2 gene on chromosome 3p21.31
was mutated in 13/15 (86%) tumours. We also observed predicted
deleterious mutations in CREBBP histone acetyltransferase in
26% of the cases and we found a broad spectrum of mutations in
other epigenetic genes previously described as frequently mutated
in B-cell lymphomas like EP300, EZH2 and ARID1 (refs 12–14).
Conversely no recurrent mutations in epigenetic regulatory
genes, like TET2, DNMT3A and IDH1/2 were observed,
while these genes are commonly mutated in other peripheral
T-cell lymphoma entities15–17. All the patients analysed
harboured at least one mutation in the JAK/STAT axis
with recurrent mutations in STAT5B (60%), JAK3 (46%) and in
the negative regulator of JAK signalling SH2B3 (20%). We
furthermore observed frequent alterations in the MAPK pathway
in 80% of EATL-II cases, including TP53 (33%), BRAF (26%),
KRAS (20%) and NRAS mutations which were essentially
mutually exclusive.
Copy number analysis derived from WES data identiﬁed
multiple regions of frequent gains and losses, essentially consistent
with previous array CGH studies8,9. In particular, we observed
gains in 9q (70% of the cases), 7q (60% of the cases), and 8q24
(comprising the MYC locus, in 35% of the cases), and recurrent
losses involving 8p, 16q, 11q, and 9p21.3 (corresponding to
the genomic localization of CDK2A/B tumour suppressor genes,
lost in 20% of the cases) (Fig. 1c, Supplementary Fig. 4 and
Supplementary Data 3). Interestingly some of the recurrently
mutated genes mapped to chromosomal regions of gains (BRAF
locus at 7q34) or losses (SETD2 locus at 3p21.31).
Highly recurrent SETD2 alterations in EATL-II. SETD2 was
found to be the most signiﬁcantly recurrently mutated gene
(MutSigCV P value¼ 2.5 10 15 and a false discovery
rate¼ 4.8 10 11), observed in 86% (13/15) of EATL-II
tumours with 20 distinctive mutations. Fourteen of these
mutations consisted of premature stop codon, non sense,
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12602








































































































































































































































































NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12602 ARTICLE
NATURE COMMUNICATIONS | 7:12602 | DOI: 10.1038/ncomms12602 | www.nature.com/naturecommunications 3
frameshift indels or splicing mutations expected to confer critical
changes in protein structure. The other six missense mutations
occurred in highly conserved residues of functional domains, and
were predicted to be deleterious with a damaging effect on the
protein by SIFT and Polyphen2 algorithms (Fig. 2a and Table 1).
We performed three-dimensional (3D) modelling and
structure stability analyses for all missense mutation covered by
the only available SET and AWS (PDB-ID 4FMU) and SRI
(PDB-ID 2A7O) domain-containing templates (Fig. 2b and
Supplementary Fig. 5). The L2486R alteration on sample 21,
the only case with a monoallelic missense mutation, was
consistently predicted as the most destabilizing mutation
(predicted DG range from 2.35 to 410 kcalmol 1, Fig. 2b). It
occurs on a critical alpha helix on the RNA pol-II binding
domain, and SETD2 binding to RNA pol II can be impaired by
the destabilized structure (Fig. 2b, Supplementary Fig. 5c)18.
All other mutations indicated destabilizing effects except
S1624C under SDM19 and Eris20; S1624C is nonetheless
predicted as disease causing in SDM. All mutations, except the
Y1579 mutation (case 22), have been functionally conﬁrmed
by IHC to lead to impaired H3K36 trimethylation. The Y1579N
mutation occurs in a highly conserved region of the SET
binding pocket, and ranks third in terms of predicted effects on
stability; nonetheless, no reduction in H3K36 trimethylation
was found in the mutated case, indicating that the phenotype that
we see cannot be explained as a function of structural alteration.
Interestingly, among the 13 SETD2-mutated cases, seven
harboured double mutations in SETD2. Moreover, CNV analysis
showed heterozygous deletion of the SETD2 locus (3p21.31) in
four cases, of which three had a concurrent monoallelic mutation
in SETD2 and one had no detectable SETD2 mutation.
To validate the CNV analysis, we developed original FISH
probes designed to identify deletions of the SETD2 locus at
3p21.31 by selecting two BAC clones hybridizing to the SETD2
locus and two BAC clones hybridizing to a preserved region on
chromosome 3 (see Methods and Supplementary Fig. 6). FISH
analysis conﬁrmed heterozygous deletion of 3p21.31 locus in the
four cases as predicted by CNV analysis and no deletion in
the other 11 cases (Fig. 2c, and Table 1). Overall 10/13 (76%)
SETD2-mutated patients seemed to have double genetic hits
affecting the gene (Fig. 2d). However, the biallelic inactivation of
SETD2 could only be conﬁrmed in the three cases with
heterozygous deletion of SETD2 locus and concurrent mutation
in the remaining allele. In the other seven cases with double
mutations, the paired mutations were too far apart to be
visualized by either sequencing chromatograms or BAM ﬁles,
and hence their biallelic nature could only be speculated.
Defective H3K36 trimethylation in EATL-II. SETD2 encodes a
methyltransferase that in humans is non-redundantly responsible
for speciﬁcally trimethylating ‘Lys-36’ of histone H3 (H3K36me3)
using dimethylated ‘Lys-36’ (H3K36me2) as a substrate21.
To determine the functional consequences of SETD2
alterations, we performed immunohistochemistry (IHC) for
semi-quantitative assessment of the SETD2–H3K36me2–
H3K36me3 axis at the protein level (Fig. 2c,d and Table 1).
Brieﬂy, both the extent of immunostainings (in quartiles from 0
to 100%, scores 0 to 4) and staining intensity (scores 0 to 3)
were evaluated and multiplied to provide an IHC score on a
scale ranging from 0 to 12. As a control, we also performed
IHC for total H3 histone, which consistently showed
strong homogeneous staining in most cells (score 12) in 10/10
cases tested.
Among the 13 SETD2-mutated cases, SETD2 IHC showed
either absent or very low expression levels of the protein
(score 0 to 3) in 9/10 evaluable cases, and a score 6 in one case
(median score¼ 0.75). H3K36me2 showed consistent nuclear
staining in 12/12 evaluable SETD2-mutated cases, with IHC
scores ranging from 4.5 to 12 (median score¼ 8). In
SETD2-mutated tumours H3K36me3 had IHC scores ranging
from 0 to 12 (median score 1) being either undetectable or very
weakly expressed (scores 0 to 2) in 10/12 evaluable cases. Given
the variation in H3K36me2 IHC scores, we also calculated in each
case the ratio between H3K36me3 and H3K36me2 IHC scores,
which ranged from 0 to 1.5 (median 0.1) in SETD2-mutated
cases. In summary, the pattern of immunostaining in most
of the SETD2-mutated cases was low SETD2 expression,
moderate to strong H3K36me2 expression, and defective
H3K36 trimethylation indicated by absent or weak detection of
H3K36me3. Accordingly, the H3K36me3/me2 ratio was o1 in
most cases. One sample (case 22) with double mutations in
SETD2 (a nonsense truncating mutation co-occurring with a
missense mutation) had an unexpected proﬁle. In accordance
with the genotype, this case was characterized by low
SETD2 expression; however, the preserved trimethylation
observed for H3K36 (IHC score 12) was discordant with
both the genotype and the reduced level of SETD2 (IHC
score 2) (Supplementary Fig. 7). Notably, the fact that three
tumours with a monoallelic SETD2 mutation showed a strong
reduction in H3K36me3 level suggests molecular alterations with
a dominant phenotype.
Recent data demonstrated that total H3K36me3 levels are not
signiﬁcantly impacted by monoallelic loss of SETD2 (ref. 22).
Accordingly in the case with a single copy loss of the SETD2
locus, and wild type remaining allele, SETD2 protein expression
was reduced (IHC score 4) but its function appeared to be
preserved (case 1) (Fig. 2c). In the only SETD2-wild type case
with no deletion of the genomic locus (case 13) SETD2 was
diffusely expressed and both H3K36me2 and H3K36me3 featured
high IHC scores (Supplementary Fig. 7).
Overall, these data strongly support a direct correlation
between SETD2 mutations and protein loss of function in
EATL-II, and indicate that reduced H3K36me3 levels may
represent an important step in EATL-II lymphomagenesis.
Figure 1 | Mutational landscape of EATL-II identiﬁed by whole-exome sequencing. (a) The proportion of transitions and transversions, the proportion of
each type of mutations, and the number of non-silent mutations, are shown individually for each of the 15 EATL-II samples analysed. The median number of
non-synonymous mutations was 57 per patient. Sample EATL-II-01, showing the highest number of mutations, originated from a recurrent tumour in a
patient previously treated with chemotherapy. Overall, missense mutations represented the most frequent type of mutation. (b) Mutations in genes
mutated in more than 3/15 patients (Z20%) and in a selection of frequently mutated genes among statistically signiﬁcantly enriched pathways (Z2
patients) are represented for each of the 15 EATL-II samples analysed and arranged by functional groups. Samples are displayed as columns and mutations
are coloured by the type of alteration. Double mutations are represented as triangles, single mutations as full coloured squares. The percentage of mutated
samples is represented on the right. Genes found signiﬁcantly recurrently mutated by MutSigCV algorithm with a false discovery rate (FDR) below 15% are
marked with an asterisk (*). (c) The Circos diagram summarizes the somatically acquired genetic variants in EATL-II genome detected by WES. From
outermost to innermost tracks: (1) ideogram representing chromosomes oriented clockwise, with centromeres indicated in red; (2–3) plot of somatic copy
number alterations and relative frequency: gains (red) and losses (blue); (4) neutral LOH distribution; (5) distribution of somatic mutations and different
mutation types across the genome colored by type of alteration. A selection of signiﬁcant genes is reported.
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JAK/STAT pathway activation in EATL-II. We found that
all 15 EATL-II cases examined by WES showed mutations
in one or more genes of the JAK/STAT pathway, with
frequent coexisting CNV or loss of heterozygosity
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STAT5B mutations were identiﬁed in nine samples (60%)
(single mutations in seven cases and double mutations involving
the same allele in two cases) and almost exclusively associated
with LOH preserving the mutated allele, suggesting that the
variants predominate in the tumour tissue. Speciﬁcally, LOH of
STAT5B locus, involving all or part of chromosome 17, was
observed in 10 out 15 EATL-II cases analysed by WGS
(Supplementary Fig. 8a), 6 of which are copy-neutral. To support
our ﬁndings, LOH status was conﬁrmed by TaqMan SNP
genotyping assay targeting a polymorphic site (rs1126821)
439 kb upstream to the STAT5B genomic locus in ﬁve cases
(Supplementary Fig. 9).
In addition to the gain-of-function STAT5B N642H variant
previously reported in EATL-II of gd derivation11, we found
other STAT5B hotspot activating mutations and a novel STAT5B
V712E variant in three tumours (Supplementary Data 1 and
Fig. 3a). Accordingly, we sought to investigate the functional
effect of the p.V712E on JAK-STAT5 activation. In HeLa
cells transfected with STAT5B-mutant constructs, the
expression of both N642H and V712E variants led to increased
STAT5B transcriptional activity and to constitutive STAT5B
hyperphosphorylation compared with the wild type (Fig. 3b),
validating the V712E variant as a new somatic gain-of-function
mutation. Six of the nine STAT5B-mutated cases were
characterized with certainty as for TCR isoform expression and
comprised three gd TCR-positive tumours, two ab TCR-positive
tumours and one case positive for both TCR isoforms
(Supplementary Fig. 8a).
JAK3 mutations found in 7/15 (46%) EATL-II cases included
several activating variants mainly in the pseudokinase domain
(A573V, M511I, R657W, K563-566del) (Fig. 3a)14,23–25 and a
novel P676R alteration which co-occurred with the M511I variant
in one case. Three cases (20%) harboured loss-of-function
mutations in SH2B3, a negative regulator of the JAK–STAT
pathway26. Two cases harboured distinct JAK1 mutations.
Alterations in other components of the pathway were not
recurrent.
Targeted analysis of additional intestinal lymphomas. Next, we
wanted to validate our WES discoveries by extending our analyses
to additional EATL-II cases, and to investigate if the characteristic
genetic aberrations of SETD2, STAT5B and other JAK/STAT
elements found in EATL-II were shared by EATL-I. For
that purpose we collected an extended cohort composed of
14 additional EATL-II, 11 EATL-I and 8 non-EATL intestinal
lymphomas of various histologies. For targeted sequencing,
we designed amplicon pools (Supplementary Table 3)
speciﬁcally interrogating the top genes mutated in EATL-II and a
selection of hotspot mutations in the JAK/STAT pathway known
to be recurrent mutated in other hematopoietic and lymphoid
tumours.
Targeted deep sequencing was applied to the 15 EATL-II cases
of the discovery cohort and essentially conﬁrmed the mutations
identiﬁed in the top mutated genes (Supplementary Table 4). It
could also be performed on 8/14 additional EATL-II tumours and
revealed SETD2 mutations in 6/8 cases, STAT5B mutations in 6/8
cases, and JAK3 and JAK1 mutations in three and one case,
respectively (Supplementary Table 5 and Fig. 4a). FISH analysis
of the 3p.21 locus was evaluable in 7/8 cases and showed
heterozygous deletion of the locus in three cases, of which two
had a SETD2 mutation and one was SETD2-wt. Consistent with
previous observations on the WES cohort, all six SETD2-mutated
cases showed overall low levels of expression of SETD2 and
H3K36me3 (Fig. 4b and Supplementary Table 6). All STAT5B
mutations were observed in cases harbouring SETD2 alterations.
Taking into account the cases of the WES cohort and the
additional eight cases with targeted sequencing, interestingly, the
two tumours with no alterations in SETD2 (case 13 and case 6)
both harboured concurrent mutations in JAK1 and JAK3.
Interestingly, no SETD2, STAT5B, JAK3 or CREBBP mutations
were identiﬁed in any of the eight EATL-I cases analysed by
targeted deep sequencing (Fig. 4a and Supplementary Table 5).
Furthermore, in four out of eight EATL-I tumours, JAK1 was
affected by missense mutations at the same amino-acid residue
G1097, a position that has been reported as frequently mutated in
anaplastic large cell lymphomas27, and two harboured hotspot
gain-of-function STAT3 mutations (N647I and K658N)28.
Overall, considering the entire cohort of cases included in this
study (15 WES EATL-II plus the extended cohort), FISH analysis
of the SETD2 locus revealed 3p21.31 loss in 7/24 contributive
EATL-II cases, in 0/11 evaluable EATL-I cases and in 0/8
intestinal lymphomas of other histotypes (Supplementary Table 6
and Fig. 4b). Moreover, IHC showed that both SETD2 and
H3K36me3 scores were signiﬁcantly higher in EATL-I and other
intestinal lymphomas, compared with EATL-II (Wilcoxon
signed-rank test, P value o0.001) (Fig. 4b,c). SETD2 expression
was highly correlated to H3K36me3/me2 ratio (Spearman’s rank
correlation, Rho¼ 0.64, P value o0.001) (Fig. 4d), with most
EATL-II clustering at the lower end of the regression line. In
contrast, EATL-I and other intestinal lymphomas exhibited high
levels of SETD2 protein expression and a H3K36me3/me2 ratio
close to 1, indicating preserved SETD2 catalytic activity.
Discussion
Our study comprising the largest EATL-II cohort analysed by
WES, provides a comprehensive genomic characterization of this
rare and aggressive lymphoma. The highlight of our ﬁndings is
the discovery of highly recurrent alterations of the SETD2 gene by
mutations and/or loss of the corresponding 3p.21 locus in490%
of the cases (21/23 cases examined by WES or targeted deep
sequencing), bringing to the light a previously unexplored genetic
player in the pathogenesis of this disease.
Figure 2 | Recurrent SETD2 alterations in EATL-II. (a) SETD2 mutations observed in EATL-II samples analysed by WES. The locations of the AWS, SET,
post-SET and WW domains of SETD2 are indicated. The region of interaction with RNA pol-II is also represented. The type and position of each identiﬁed
mutation is shown. Across species, homology of SETD2 amino-acid changes was determined by multiple sequence alignment. The high level of
conservation of these sites among species indicates that the SETD2 mutations all target conserved residues. (b) Computational modelling of the L2486R
SET2 variant. The L2486R residue lies within one of the critical alpha helices structurally supporting the RNA pol-II binding site. This mutation was
consistently predicted to be destabilizing (DG40 kcalmol 1) with structure-based methodologies (predicted DG between 2.35 to410 kcalmol 1). Note
the predicted changes in side chains of critical SRI domain residues. (c) Morphology (haematoxylin and eosin, original magniﬁcation 400), FISH (3p21.31
locus, original magniﬁcation  630) and immunohistochemical stainings for SETD2, H3K36me2 and H3K36me3 (immunoperoxidase, original
magniﬁcation 400) in four EATL-II cases with different types of SETD2 gene alterations (EATL-II-14: double hits missense and nonsense mutations;
EATL-II-12: missense mutation and heterozygous 3p21.31 deletion; EATL-II-3: one frameshift indel mutation; EATL-II-1: no mutations but heterozygous
3p21.31 loss). R and G denote ‘red’ and ‘green’ signals to indicate the most common FISH hybridization pattern seen in each nucleus. (d) Summary of SET2
gene alterations and SET2 function in the 15 EATL-II analysed by WES. Mutations of SET2 are represented in dark blue and SET2 locus deletion in light blue.
NA, not analysed; NL, not lost.
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SETD2 encodes a lysine methyltransferase responsible for
histone H3 lysine 36 trimethylation (H3K36me3), which interacts
with RNA polymerase II and is recruited to sites of active
transcription29. Among various genes coding for enzymes with
methytransferase activity, SETD2 shows a very high frequency of
somatic mutations in various cancer types, with high incidence of
deleterious and loss-of-function mutations supporting its tumour
suppressor function29. The tumour suppressor role of SETD2 is
emerging in several cancer types, including clear cell renal cell
carcinoma, breast and lung cancers, acute lymphoblastic
leukaemia, high-grade gliomas and gastrointestinal stromal
tumours30–34. SETD2 inactivation has been demonstrated as a
critical event in facilitating both disease initiation and progression
through decreasing H3K36me3 (ref. 33).
Our study deﬁnes the genetic inactivation of SETD2 as a
hallmark of EATL-II, and shows for the ﬁrst time highly
prevalent SETD2 deregulation in a cancer of mature lymphocytes.
Of 23 EATL-II cases with complete genomic SETD2 assessment,
19/23 (83%) were SETD2-mutated, 7/23 (30%) had loss of one
SETD2 locus, and overall 21/23 (91%) had SETD2 genomic
alteration. The high frequency of SETD2 alterations and the
mutational spectrum strongly supports the tumour suppressor
role of SETD2 in EATL-II. In fact, we found that 18 of the total 26
mutations (69%) identiﬁed in our ETAL-II cases were either
nonsense (6) frameshift indels (9) or splicing mutations (3)
predicted to impair protein function and distributed along the
whole gene. Instead, all the missense mutations tended to cluster
in functional domains of the SETD2 protein and were predicted
to be probably damaging. Although only ﬁve mutations have been
previously described in COSMIC (Supplementary Data 1 and
Supplementary Table 5), the SETD2 mutational spectrum in
EATL-II well overlapped with the pattern of mutations found in
other cancer types33–35. In accordance with the notion that
multiple hits on the same gene are generally required for
inactivating the function of tumour suppressor gene, we found
that the majority of the cases (12/21) had double genetic hits
affecting SETD2 either by double mutations (7/12) or concurrent
3p21.31 loss and SETD2 mutation in the remaining allele (5/12).
Although for technical reason we could not formally demonstrate
that the double SETD2 mutations corresponded to mutations on
both alleles, we can reasonably speculate that these mutations are
biallelic. In fact biallelic inactivation of SETD2 gene has been
previously demonstrated in other cancer types by both double
mutations occurring on separate alleles of SETD2 in individual
patients with acute leukaemias33 or by concurrent 3p loss and
loss-of-function SETD2 mutation in the remaining allele in renal
cell carcinomas22. We additionally showed that SETD2 mutations
overall correlate with complete loss or strong reduction in
H3K36me3, suggesting that these are indeed loss of function.
Interestingly, we observed that not only double inactivating hits
Table 1 | Summary of SETD2 genomic status (mutations and copy number) with phenotypic correlation (expression of SETD2 and























1 SETD2 WT Heterozygous
deletion
4 12 8 8 1
2 SETD2 Splicing No deletion exon 20-21 Splicing 20-21 0 0 6 12 8 2 0.25
Missense exon5 p.C1533Y Damaging Probably
damaging
3 SETD2 Frameshift indel No deletion exon14 p.T2037fs 0 0 1 12 6 1 0.17
4 SETD2 Splicing Heterozygous
deletion
exon 13-14 Splicing 13-14 0 0 0 NA 8 1.5 0.19
12 SETD2 Missense Heterozygous
deletion
exon8 p.N1643K Damaging Probably
damaging
0.5 12 12 6 0.5
13 SETD2 WT No deletion 10 12 10 12 1.2
14 SETD2 Missense No deletion exon6 p.M1607I Damaging Probably
damaging
0 12 10 1 0.1
Nonsense exon3 p.R1459X Tolerated 0
15 SETD2 Frameshift indel No deletion exon6 p.A1597fs 0 0 NC 12 4.5 0 0
17 SETD2 Frameshift indel No deletion exon21 p.K2546fs 0 0 0 NA 6 0 0
Frameshift indel exon12 p.P1934fs 0 0
20 SETD2 Frameshift indel No deletion exon3 p.F573fs 0 0 1 12 12 1 0.08
Splicing exon1-2 Splicing 1-2 0 0
21 SETD2 Missense No deletion exon20 p.L2486R Damaging Probably
damaging
2 NA 8 0.5 0.06
22 SETD2 Nonsense No deletion exon15 p.R2121delinsX 0 0 2 12 8 12 1.5
Missense exon6 p.Y1579N Damaging Probably
damaging
24 SETD2 Nonsense Heterozygous
deletionw
exon3 p.G975X Damaging 0 NC 12 6 0 0
25 SETD2 Nonsense No deletion exon21 p.Y2543X Tolerated 0 0.5 NA 4.5 0 0
Frameshift indel exon3 p.C530fs 0 0
26 SETD2 Frameshift indel No deletion exon17 p.T2388fs 0 0 NC NA NC NC NC
Missense exon7 p.S1624C Damaging Probably
damaging
NA, not analysed; NC, non contributive.
The possible impact of amino-acid substitutions on SETD2 function was predicted by using SIFT and PolyPhen algorithms. The two algorithms do not predict functional consequences of truncating
mutation (stop gain, splicing and inframe indel) as their impact on protein function is very likely to be disease causing/damaging.
*HDIV: HumDiv PolyPhen-2 prediction model.
wIn case 24, hybridization with RP11-425J9 showed a normal pattern; heterozygous deletion of SETD2 locus (3p21.31) was evidenced with RP11-650F17 probe.
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but also monoallelic SETD2 mutations impaired histone H3K36
trimethylation supporting the notion of a dominant phenotype.
This observation is in accordance with ﬁndings reported by
other groups in high-grade gliomas or gastro-intestinal stromal
tumours with single SETD2 mutations32,34. In addition,
monoallelic constitutive mutations in SETD2 were identiﬁed as
the causative event in some cases of Sotos-like syndrome, an
observation which offers a direct proof that monoallelic
mutations in SETD2 may have a direct pathogenic role36. In
one case with only 3p21 heterozygous deletion, H3K36 was still
detected at relatively high levels, in accordance with ﬁndings from
others demonstrating that total H3K36me3 levels are not
signiﬁcantly impacted by monoallelic loss of SETD2 (ref. 22).
Mutation-induced deregulation and activation of the
JAK–STAT pathway, which is normally engaged by various
cytokines, has emerged over the past years as a major oncogenic
mechanism in several T- and NK-leukaemia and lymphoma
entities11,24,27,28,37. Here we demonstrate that all EATL-II cases
show mutations with frequent coexisting CNV or LOH in one or
more genes of the JAK/STAT pathway, which is also known to
regulate intraepithelial lymphocyte function38–40. Recurrent
mutations of STAT5B in EATL-II were ﬁrst reported by Kucuk
et al. in 7/19 cases analysed in their study, and in that series
occurred exclusively in tumours derived from gd-T cells11.
Here we found a higher incidence of mutations in STAT5B
(17/23 cases, 74%), which was the most frequently mutated gene
in the pathway. Our ﬁndings are closer to those reported very
recently by Nairismagi et al.10 who found STAT5B mutations in
63% of the cases in a series of EATL-II from Asia. In common
with the latter report, STAT5B mutations in our study were not
restricted to tumours with gd-TCR expression. The novel
STAT5B variant (V712E) was discovered in both studies and
validations performed independently by both groups
convincingly point at a novel activating mutant. In addition,
frequent neutral LOH at STAT5B locus was also observed,
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Figure 3 | Recurrent alterations targeting the JAK/STAT pathway in EATL-II. (a) Schematic representation of somatic alterations in STAT5B and JAK3
identiﬁed in this study. The functional domains of the proteins are shown. Filled rectangles represent mutations that have been previously described
(red: missense mutation and blue: indel). Empty rectangles indicate previously unreported mutations. (b) Luciferase assay was performed in Hela cells
co-transfected with the STAT5B constructs (WT, V712E and N642H) or empty vector together with a luciferase sequence under the control of a
STAT5-binding element. Luciferase assay was performed in three independent experiments. Each condition was tested in triplicate and the fold change was
normalized with the relative luciferase activity of the empty vector. Each column represents mean±s.d. of three independent experiments. Both mutants
clearly induced increased luciferase activity when compared with the wild-type STAT5B plasmid. (c) P-STAT5(Y699) and STAT5 protein expression levels
in Hela cells transfected with STAT5B wild-type or mutant constructs V712E and N642H are shown by western blotting. Non-transfected cell line (NT) and
cell line transfected with an empty vector (GFP) were used as controls for the reaction. STAT5B variants (V712E and N642H) led to increased
phosphorylation of STAT5B as compared with the ectopic expression of the STAT5B-WT. The transduction efﬁciency for each condition was assessed by
total STAT5B and GFP expression. One experiment representative of three independent experiments is shown. Western blotting results were congruent
with the luciferase assay, conﬁrming the constitutive hyperphosphorylation of both N642H and V712E STAT5B variants.
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lymphomagenesis. The frequent occurrence of JAK3 mutations is
another common ﬁnding, in one-third of the cases in the study
from Asia and in about half of our cases (12/23). Moreover, we
also report less frequent but recurrent mutations in SH2B3 (20%)
and in JAK1. We also observed that mutations affecting the
JAK/STAT pathway overall are not mutually exclusive. In
accordance with the observation that in other T-cell-derived
neoplasms, STAT5B mutations tend to correlate with aggressive
diseases while STAT3 mutations occur at high frequency in
indolent leukaemias24,28,41, interestingly, in EATL-II, the very
high prevalence of STAT5B alterations also contrasts with
the absence of STAT3 mutations. Within our WES cohort,
two patients harboured distinct mutations in GNAI2, a member
of the family of G-alpha proteins involved in G-protein-coupled
receptor signalling pathway, which was recently discovered10 as
recurrently (20%) mutated in EATL-II (Supplementary Data 1)
The interplay between the JAK/STAT and the MAPK pathways
is well known, as the engagement of cytokine receptors
also activates the MAPK cascade42. The fact that we found
high frequency and not mutually exclusive mutations in these
two pathways suggests potential synergy in EATL-II
lymphomagenesis.
The comparative analysis of the classical type of EATL (type I)
was limited to a relatively small number of cases but clearly
indicates a genomic proﬁle distinct from EATL-II, since no
alterations in SETD2 were observed in any of the eight EATL-I
analysed. Mutation-induced activation of the JAK/STAT pathway
seems to be a feature of EATL-I as well, but relies on alterations in
genes that are distinct from those most frequently involved in
EATL-II: in particular, whereas no STAT5B mutations were
identiﬁed in any of the eight EATL-I tumours tested, recurrent
mutations in JAK1 and STAT3 were observed.
In conclusion, our study uncovers a unique genetic proﬁle of
EATL-II characterized by highly recurrent loss-of-function
SETD2 alterations and mutations affecting the JAK/STAT and
MAPK pathways, supporting that a combination of epigenetic
deregulation and cell signalling activation are major oncogenic
events in the pathogenesis of this disease. At the same time, our
ﬁndings open new avenues for the development of targeted
therapies representing a highly unmet medical need for EATL-II
patients. Notably, it has recently been demonstrated that
H3K36me3-deﬁcient cancers can be selectively targeted by a
WEE1 inhibitor (AZD1775) (ref. 43), which might therefore
constitute a new therapeutic option. Last, our analyses also
substantiate that EATL-I and EATL-II are genetically different
and represent distinct clinical entities.
Methods
Cases studied. Twenty-nine cases of EATL-II, 16 EATL-I and eight intestinal
lymphomas of various histologies were retrieved from the ﬁles of the Pathology
Departments of Lausanne (Switzerland), Creteil, Bordeaux, Lille and Nantes
(France), and Tuebingen (Germany). The demographics of the patients and
pathological features of the EATL-II cases analysed by deep sequencing are
summarized in Supplementary Table 1.
The use of samples from France was approved by the Comite´ de Protection des
Personnes – Ile-de-France IX (CPP08/009), and the use of German samples by the
Ethical Committee of the University of Tuebingen (105/2013BO2). The study
protocol was approved by the Commission cantonale d’e´thique de la recherche sur
l’eˆtre humain (Lausanne) (protocol 382/14). Informed consent could not be
obtained from all subjects included in this retrospective study of a rare disease
entity. Many patients were deceased at the time the study was initiated.
The institutional review board (Lausanne Ethical Committee) was fully informed
and consented to the study. All samples are used in accordance with the
Declaration of Helsinki.
Sample selection and preparation for sequencing. Fifteen cases of routinely
processed (FFPE) surgical specimens of EATL-II were selected for availability of
tumour and matching non-tumoural intestinal tissue. Areas with highest tumour
cell content and those devoid of neoplastic cells were marked on HE slides by a
pathologist and subsequently reported on corresponding FFPE sections stained
with toluidine blue. Manual microdissection of the regions of interest was
performed under a microscope, followed by genomic DNA extraction (Maxwell 16
FFPE Plus LEV DNA Puriﬁcation Kit, Promega).
Whole-exome sequencing. We developed and validated an in-house exome
sequencing protocol and bioinformatic pipeline for FFPE samples by comparing
WES of two cases of intestinal lymphomas for which matched frozen and FFPE
blocks with paired normal and tumour tissue were available (cross-validation of
FFPE and fresh-frozen mutation data—Supplementary Figs 2 and 3). Since we
noticed that the amount of DNA recovered after shearing (Covaris Inc.) strongly
depends on the DNA degradation status, we measured and normalized the starting
material for library preparation after the sonication process. To decrease the
duplication rate and thus achieve a sufﬁcient coverage and high sequencing depth
we combined the KAPA HTP library preparation kit (Kapa Biosystem) with the
SureSelectXT Target Enrichment System (Agilent Technologies). Brieﬂy, 200 ng of
sheared DNA was end-repaired, extended with an A base on the 30 end, ligated
with Agilent-adaptors and pre-capture ampliﬁed with KAPA HTP library
preparation kit. Exome capture was performed following the Sure Select targeted
enrichment system for pair-end sequencing library protocol. Six captures were
pooled further and in two lanes to a ﬁnal equivalent of three exomes per lane on a
HiSeq 2500 system (Illumina Inc).
Sequence analysis. The analysis of the whole-exome sequence was based on
established algorithms and pipelines according to the GATK (The Genome
Analysis Toolkit) standards (Best practice variant detection with the GATK v.4, for
release 2.0)44. Initial QC steps involved demultiplexing, quality assessment of the
produced reads and adapter removal. Forward and reverse reads were aligned to
the human genome (GATK repository, build 37 decoy) using BWA-MEM
(v0.7.5a)45. BAM ﬁles were subjected to PCR duplicate removal (Picard v1.119),
followed by realignment around indels and base recalibration using GATK tools
(v3.2-2). Single nucleotide and Indel variant calling was performed using samtools
mpileup (v1.2) and VarScan (v2.3.7)46 on the on-target BAM ﬁles obtained for
each patient using the following parameters: samtools—minimum mapping
quality¼ 1, coefﬁcient for downgrading mapping quality¼ 50, minimum number
gapped reads for indel candidates¼ 3 and minimum fraction of gapped
reads¼ 0.0002; VarScan somatic algorithm—minimum variant allele frequency
threshold¼ 0.08, tumour purity 0.9, minimum read depth at a position to make a
call¼ 10 and Somatic P value¼ 0.1 (Fisher’s Exact Test). Raw variant calls were
annotated for presence in the dbSNP and COSMIC databases as well as mutation
effect on gene transcript by Annovar (v.2015-06-17)47. Further variant ﬁltering was
carried out in R keeping variants that showed an allele frequency Z22% in the
tumour counterpart while having allele frequency o15% in the normal as well as
Figure 4 | EATL-II has a genetic proﬁle distinct from EATL-I and other intestinal lymphomas. (a) Summary of mutations in a selected panel of genes
examined by targeted deep sequencing in 23 EATL-II and 8 EATL-I cases. Mutations are represented in dark blue. Loss of SETD2 locus is reported in light
blue when present in the absence of mutation (b) Morphology (haematoxylin and eosin, original magniﬁcation 400), FISH (3p21.31 locus, original
magniﬁcation 630) and immunohistochemical stainings for SETD2, H3K36me2 and H3K36me3 (immunoperoxidase, original magniﬁcation 400) in
three intestinal lymphomas representative of EATL-II, EATL-I and other histotypes (ENKTCL: extranodal NK/T-cell lymphoma). R and G denote ‘red’ and
‘green’ to indicate the most common FISH hybridization pattern seen in each nucleus. (c) Immunohistochemistry results for SETD2 and H3K36me3 levels
in EATL-II, EATL-I and other intestinal lymphomas. The SETD2 gene status is colour-coded. Red indicates SETD2 alteration (heterozygous loss and/or
mutation(s)); blue, SETD2-WT; black, unknown SETD2mutation status. Wilcoxon signed-rank test, **highly signiﬁcant (P valueo0.001), NS, non signiﬁcant
(P value 40.05). The top, the middle and the bottom lines of the boxes show the ﬁrst, the second (median) and the third quartiles of the proteins score,
respectively. Whiskers represent the scores that are 1.5 times the interquarile range (IQR) above or below the ﬁrst and the third quartiles. (d) H3K36me3
levels normalized to those of H3K36me2 (H3K36me3/me2 ratio) were plotted against SETD2 IHC score for all patients of the extended cohort with
complete characterization (21 EATL-II, 15 EATL-I and 8 other intestinal lymphomas). A highly signiﬁcant correlation was observed between SETD2
expression and H3K36me3/me2 ratio score (Spearman’s rank correlation; P value o0.001).
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having at least 18 reads supporting the reference sequence and more than 5 reads
supporting the variant. In addition, the differences in frequency between tumour
and normal were set to be Z22%. Variants were also excluded if part of the false
positive genes reported by Fajardo et al.48 or if described to be an SNP with MAF
(minimum allele frequency) o2% in either the 1000Genome project (v.Oct2014)
or NIH-Exome Sequencing Project (ESP6500—European ancestry subset).
MutSigCV (v1.4) was used to identify genes with a mutation frequency higher than
expected49.
Copy number analysis was performed using the algorithm Somatic Copy
Number Alteration Calling in VarScan by comparing pairs of tumour and normal
samples. Raw counts were imported in R, log transformed and smoothed by
computing the median using bin of 100 kb. DNAcopy (v1.40) and cghMCR (v1.24)
packages were used to identify genomic regions with altered copy number. This
was obtained by smoothing the data to remove single point outliers before applying
a circular binary segmentation algorithm, which tests the signiﬁcance of the
alteration by using a hybrid approach50. Segments with ratio over 0.25 or under
 0.25 and more than eight supporting markers were considered as ‘gain’ or ‘loss’,
respectively. Except when indicated, all analysis was carried out using either an
assortment of R system software (http://www.R-project.org, v3.1.2) packages
including those of Bioconductor (v3.1) or original R code.
Evaluation of mutation effects on SETD2. We predicted effects on stability of all
six missense mutations on SETD2 using various methods19,20,51–54. With the
exception of I-Mutant, which can make predictions in both sequence and structure
mode, all predictions were made based on the SET and AWS (PDB-ID 4FMU) and
SRI (PDB-ID 2A7O) domain structures. The SET domain structure was in a
non-native, active conformation. We also created models of mutation effects on
side chain positions using ANDANTE55, as implemented in SDM19.
Pathway enrichment analysis. We assessed for enriched pathways in EATL
type-II by checking if both the proportion of cases bearing at least one event
(deﬁned as either a mutation or genomic alteration) in a pathway as well as the
degree by which pathways are altered in each patient, exceeded the corresponding
random expectation. We used a custom signature set comprised of the MSigDB
KEGG (n¼ 185) and hallmark signatures (n¼ 50), as well as a customized list of
known epigenetic modiﬁers from literature56. Brieﬂy, we constructed a binary
event matrix, MB, comprised of all mutations and genomic events per sample.
We used MB to construct a second matrix containing the frequency of events per
signature per patient (Msig patient). To estimate the corresponding random
expectation, we performed 1,000 row permutations of MB and from which 1,000
random Msig patient, rnd matrices were derived. Given that rows of Msig patient are
normally distributed, we performed a one-sided t-test to check if the Msig patient
mean is greater than Msig patient, rnd. Calculated P values were adjusted according
to the Benjamini and Hochberg method57 to control for false positives.
Sanger sequencing. Sanger sequencing was used to benchmark our variant call
pipeline. Twenty-nine variants were selected among the relevant deregulated genes.
DNA regions of interest were ampliﬁed using speciﬁc primers targeting exonic
regions containing the variant (Supplementary Table 2). Puriﬁed PCR products
were sequenced in the forward and reverse directions using ABI PRISM BigDye
Terminator Cycle Sequencing Ready Reaction kits (V.3) and an ABI PRISM 3730
Genetic Analyzer (Applied Biosystems).
Targeted deep sequencing. Targeted resequencing was used to validate some of
the recurrently mutated genes identiﬁed by WES in 15 EATL-II, and to assess their
mutational status in eight additional EATL-II and 8 EATL-I samples. For
orthogonal validation of the 15 cases examined by WES, only tumour DNA was
deep sequenced. Among the additional 16 cases, paired normal/tumour DNAs
were sequenced in 10 (two EATL-II and eight EATL-I) with matching normal
tissue available, and only tumour DNA was sequenced in eight EATL-II without
matching normal tissue available.
The Ion AmpliSeq designer software was used to generate three highly speciﬁc
panels consisting of 281 amplicons (amplicon range 125–175 bp), covering the
whole coding sequence of SETD2, CREBB and JAK1 and the most recurrent
mutation hotspots in JAK3 and STAT5B and other JAK and STAT family members
described in hematopoietic or lymphoid tumours (COSMIC) and in our EATL-II
cohort (Supplementary Table 3).
DNA libraries were prepared using the Ion AmpliSeq Library Kit v2 and the Ion
OneTouch automated systems according to the manufacturer’s instructions.
Samples were sequenced on the Ion 318 Chip kit v2 (Life Technologies). The mean
coverage for tumour and normal was 876 and 803 , respectively, with 96% of
the target regions covered above 100 .
Alignment was performed using Novoalign v3.02.07 according to the default
setting. Mutations were called using Varscan v2.3.7 and annotated with
ANNOVAR. SNVs and indels were ﬁltered based on the following three
conditions: (1) minimum coverage of 100; (2) minimal variant frequency 15%; and
(3) P value (Fisher’s Exact Test) for somatic variant40.1. When matching normal
DNA was available, direct comparison was performed applying the following ﬁlter
for SNVs and indels call: minimum variant allele frequency threshold¼ 0.08,
tumour purity 0.9, minimum read depth at a position to make a call¼ 10 and
Somatic P value¼ 0.1 (Fisher’s Exact Test). Furthermore, we kept only variants that
showed an allele frequency 415% in the tumour counterpart while having allele
frequency o10% in the normal as well as having at least 18 reads supporting the
reference sequence and more than ﬁve reads supporting the variant. In addition,
the differences in frequency between tumour and normal were set to be Z15%.
Discrepancies with exome sequencing were resolved by visual inspection with IGV
software to conﬁrm or refuse the candidate alteration.
Immunohistochemistry. IHC staining was done on 4 mm FFPE sections from
native blocks and from a tissue microarray comprising cores representative of a
subset of EATL-II cases. Reactive tonsils were used as external controls for all
staining. Brieﬂy, after deparafﬁnization, antigen retrieval was performed in
Tris/EDTA pH 9.0 in a pressure cooker respectively 1.30min for Histone H3,
H3K36me3 and H3K36me2 and 5min for SETD2. Slides were incubated
with Histone H3 (Abcam, ab1791, dilution 1:1,000), H3K36me3 (Abcam, ab9050,
dilution 1:2,000) or H3K36me2 (Abcam, ab 9049, 1: 4,000) or SETD2 (Sigma,
HPA042451, 1:400) antibodies for 1 h at room temperature. Antibody detection
was performed with diaminobenzidine detection system (Dako), according to the
manufacturer’s instructions. For SETD2 we used a C-terminal SETD2 antibody that
would not detect SETD2 affected by protein truncations distal to the reported
mutations. Two pathologists independently performed quantiﬁcation of
H3K36me3, H3K36me2 and SETD2, blinded to the SETD2 genotype. The
individual scores were overall concordant and the cases were reviewed for
consensus ﬁnal scoring. Speciﬁc attention was paid to the cases that showed
discordant genotype/phenotype.
A semi-quantitative scoring scale was applied, based on both the extent and
intensity of the staining as previously published58. Staining of o10% of stained
tumour cells was considered negative (score 0); scores 1, 2, 3 and 4 corresponded to
positivity in 10–25%, 26–50%, 51–75% and 76–100% of tumour cells, respectively.
Negative stainings with no internal positive control were not interpreted.
For staining intensity, scores 1, 2 and 3 were attributed to weak, moderate and
strong intensities, respectively; undetectable staining was scored 0. To provide a
common global scale, the extent score and the intensity score were multiplied
with a scoring scale ranging from 0 to 12. Furthermore, the ratio of H3K36me3
score to that of H3K36me2 score was calculated to normalize the level of
trimethylation and correct for difference across different samples with
heterogeneous bimethylation levels.
FISH assays. To validate CNV data from WES, we developed original FISH
probes designed to identify deletions of the SETD2 locus at 3p21.31. Bacterial
artiﬁcial chromosome (BAC) clones were chosen using the UCSC (University of
California Santa Cruz) Genome Browser website (http://genome.ucsc.edu, February
2009 assembly) and purchased from BACPAC Resources. We selected two BAC
clones hybridizing to the SETD2 locus (target probes at 3p21.31: RP11-425J9 and
RP11-650F17, GenBank references AC094020.2 and AQ463932.1/AQ511510.1,
respectively) and two BAC clones hybridizing to a preserved region on
chromosome 3 (control probe at 3p25: RP11-266J6 and RP11-485N3, GenBank
references AC011610.11/AC022382.4 and AQ633871.1/AQ633873.1, respectively),
as illustrated in Supplementary Fig. 3. Following overnight culture, BAC DNA
was extracted (Qiagen Plasmid Maxi Kit, Qiagen) and ﬂuorescently labelled
by nick translation (Nick Translation Kit, Abbott Molecular). BACs constituting
the target probes were labelled with SpectrumOrange-dUTP and those forming
the control probe with SpectrumGreen-dUTP (Abbott Molecular), and
resuspended at 100 ng ml 1 in LSI/WCP Hybridation Buffer (Abbott Molecular).
Each BAC was tested separately on metaphase spreads from normal
peripheral blood, in conjunction with a centromeric probe for chromosome
3 (Vysis CEP3 (D3Z1) SpectrumOrange Probe, Abbott Molecular), to
verify hybridization to the expected chromosomal region and rule out any
cross-hybridization.
FISH labelling was performed using the Histology FISH Accessory Kit (Dako)
according to the manufacturer’s protocol, with minor modiﬁcations. After
dewaxing and rehydration, 4-mm-thick tissue sections were heated in pre-treatment
solution (Dako) for 10min in a water-bath at 95 C. Slides were then digested with
pepsin (Dako) for 13min at 37 C on an open preheated hybridizer (Dako).
Following dehydration, FISH probes were placed onto the section and covered with
sealed coverslip. Codenaturation (5min at 73 C) and hybridization (overnight at
37 C) of probes and sample were successively carried out in a closed humidiﬁed
hybridizer. After coverslip removal, probe excess was washed in 2 SSC/0.3%
Tween20 for 2min at 73 C followed by 2 SSC/0.1% Tween20 for 2min at room
temperature. Finally, slides were dehydrated and mounted with DAPI I
counterstain (Abbott Molecular) and maintained at 4 C in the dark.
Labelled slides were analysed with a Zeiss AxioImager Z2 ﬂuorescence
microscope equipped with speciﬁc ﬁlters for FITC, SpectrumOrange, DAPI, and
double and triple band-pass ﬁlters. Hybridization signals were examined with a
Plan-APOCHROMAT  63 oil immersion objective. Images were captured using
ISIS digital image analysis system version 5.5 (Metasystems).
To establish the cutoff for SETD2 locus deletion, we recorded the hybridization
patterns of at least 200 nuclei in ﬁve negative control samples (reactive tonsils from
healthy individuals). A nucleus was considered deleted for SETD2 locus if the ratio
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between the orange signals (target probe) and the green signals (control probe) was
r0.5. We thereby obtained a cutoff value of 11.2%, computed as the mean
percentage of nuclei with SETD2 locus deletion (false-positive ﬁndings) plus three
s.d.’s, in line with published recommendations.
The evaluation of SETD2 locus in tumour samples was carried out in the
regions with highest tumour cell content, selected using the DAPI ﬁlter under the
guidance of corresponding HE slides. For each case, the hybridization patterns of at
least 100 tumour nuclei were recorded. If the percentage of nuclei with SETD2
locus deletion was above the cutoff value of 11.2%, the case was considered deleted.
STAT5B mutagenesis. An expression plasmid pCMV6-Entry containing the
wild-type sequencing of STAT5B (OriGene) was used as a template for
site-directed mutagenesis to generate STAT5B mutants for functional study.
STAT55-N642H and STAT5B-V712E mutants were generated using the
Quick-change Site-directed Mutagenesis kit (Agilent Technology), according to the








Full sequencing of the inserts was performed to conﬁrm the presence of the
introduced mutations and to ensure that no additional variants were added during
the mutagenesis reaction.
After mutagenesis STAT5B-WT, -N642H and -V712E cDNAs were PCR-
cloned into the multiple cloning site of the pRRL-PGK-T2A-GFP lentiviral
expression vector (kindly provided by Dr George Coukos) using BclI and NheI
restriction sites.
Cell line. Hela cell line from American Type Culture Collection (ATCC) was
maintained in DMEM (Sigma-Aldrich) containing 10% FBS and supplemented
with 2mM L-glutamine and 1% Penicillin–Streptomycin, at 37 C and 5% CO2.
Transient transfection and luciferase assay. Eighty per cent of conﬂuent
Hela cells were transiently transected with pRRL-PGK-T2A-GFP–STAT5B/WT, /
N642H, /V712E and with empty vector respectively using Lipofectamine 2000
(Thermo Fisher) according to manufacturer’s instructions. Cells were
simultaneously co-transfected with pGL4.52 vector, a luciferase report construct
with a STAT5 responsive element luc2P/STAT5 RE/Hygro (Promega), and with a
renilla luciferase pRL-TK plasmid (Promega). After 48 h transfection, The
Dual-Luciferase Reporter Assay System (Promega) was used to determine
luciferase activity according to the manufacturer’s recommendations. Fireﬂy and
renilla luciferase activities were measured sequentially; results were expressed as
ratios of ﬁreﬂy luciferase activity over renilla luciferase activity. The experiments
were performed in triplicate.
Western blotting. Hela cells were lysated after 48 h transfection with pRRL-PGK-
T2AGFP–STAT5B WT and mutant constructs. Non-transfected cell line and cell
transfected with an empty vector were used as internal control for the reaction.
Standard western blot analysis was carried out. RIPA buffer supplemented with
protease inhibitors cocktail (Sigma Aldrich) and phosphates inhibitor cocktail
(Sigma Aldrich) was used for protein extraction. Proteins were transferred to a
polyvinylidene diﬂuoride membrane, after which the membrane was blocked with
Super Block (Thermo Fisher) blocking buffer for 1 h. Primary antibodies for
STAT5B were obtained from Cell Signal Technology: STAT5B Rabbit mAb#9363
dilution 1:1,000 in 5% milk and Phospho-Stat5 (Tyr694) (D47E7) Rabbit mAb
#4322 dilution 1:500 in Super block. Monoclonal Anti-Actin (Clone AC-40) and
anti-GFP (clone GFP-20) antibodies were purchased from Sigma Aldrich and used
to a working dilution of 1:1,000. Membranes were incubated overnight at þ 4 C.
Uncropped representative WB images are shown in Supplementary Fig. 11.
LOH on chromosome 17. To validate LOH observed on chromosome 17, we
performed a TaqMan SNP genotyping assay using QuantStudio 3D digital
PCR. Starting from our WES data, we selected the SNP rs1126821 (assay ID:
C_153647_20) which was observed to be polymorphic in ﬁve samples (four with
LOH and one with no alterations in that locus) and at B439 kb upstream to
the genomic locus for STAT5B gene. All the assays were performed following
manufacturer’s instructions and analysed with QuantStudio 3D Analysis Suite
Cloud Software.
Data availability. The VCF ﬁles containing the somatic variants of the samples
analysed by whole-exome sequence have been deposited in the European Genome
Archive (EGA) under accession code EGAS00001001879. SET and AWS domain
structures (PDB-ID 4FMU) and the SRI domain structure (PDB-ID 2A7O) were
obtained from PDB. All other data are available in the paper and Supplementary
Information ﬁles, or available from the author upon request.
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